2009;169:832 42. 9.7. Metabolic Syndrome S9.7-1. Lim S, Eckel RH. Pharmacological treatment and therapeutic perspectives of metabolic syndrome. Rev Endocr Metab Disord. 2014;15:329 41. S9.7-2. Owen JG, Reisin E. Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evi- dence, meta-analysis, post hoc and guidelines publications. Curr Hypertens Rep. 2015;17:558. S9.7-3. Ruderman NB, Shulman GI. Metabolic syndrome. Jameson JL. Endocrinology: Adult & Pediatric. 2015; Elsevier Saunders: Philadelphia, PA:752 9. S9.7-4. Mozumdar A, Liguori G. Persistent increase of prevalence of meta- bolic syndrome among U.S. adults: NHANES III to NHANES 1999 2006. Diabetes Care. 2011;34:216 9. S9.7-5. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167 74. S9.7-6. Chen J, Gu D, Chen C-S, et al. Association between the metabolic syndrome and chronic kidney disease in Chinese adults. Nephrol Dial Transplant. 2007;22:1100 6. S9.7-7. Barzilay JI, Davis BR, Whelton PK. The glycemic effects of anti- hypertensive medications. Curr Hypertens Rep. 2014;16:410. S9.7-8. Kostis JB, Wilson AC, Freudenberger RS, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005;95:29 35. S9.7-9. Wright JT Jr, Harris-Haywood S, Pressel S, et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syn- drome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2008;168:207 17. S9.7-10. Wright JT Jr, Probstfield JL, Cushman WC, et al. ALLHAT find- ings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med. 2009;169:832 42. S9.7-11. Black HR, Davis B, Barzilay J, et al. 